What kind of evidence is included on the MOTS-C research history page?

Only PubMed-verified publications and explicitly labeled editorial-review gaps are included.

Does this page provide medical advice or human-use guidance?

No. Atlas provides an educational publication map and does not provide sourcing, human-use instructions, or individual medical guidance.

Authority cluster

A publication timeline built only from verified study records.

2015The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Study →
2019MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus.Study →
2022The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.Study →
2022MOTS-C, the most recent mitochondrial-derived peptide in human aging and age-related diseases.Study →
2023MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.Study →
2023MOTS-c Functionally Prevents Metabolic Disorders.Study →
2023MOTS-C: A potential anti-pulmonary fibrosis factor derived from mitochondria.Study →
2023Role of MOTS-c in the regulation of bone metabolism.Study →
2024Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.Study →
2024MOTS-c modulates skeletal muscle function by directly binding and activating CK2.Study →